Abstract
When the inflammation of ankylosing spondylitis (AS) subsides, it may be replaced by repair tissue and fatty lesions, a process that leads to osteoproliferation and development of syndesmophytes. This article presents results from the European Ankylosing Spondylitis Infliximab Cohort [EASIC] study, an open-label extension of the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy [ASSERT]. The objective of the EASIC study was to directly compare the effect of inflammation and fatty degeneration on the development of syndesmophytes in patients with AS after 5 years of anti-TNF therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
